Nuclear Medicine and Cancer Theragnostics: Basic Concepts

Nuclear Medicine and Cancer Theragnostics: Basic Concepts

Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging through linkage to a proper radionuclide, and the other bearing an alpha- or beta-emitt...

Full description

Bibliographic Details
Main Authors:	Vasiliki Zoi, Maria Giannakopoulou, George A. Alexiou, Penelope Bouziotis, Savvas Thalasselis, Andreas G. Tzakos, Andreas Fotopoulos, Athanassios N. Papadopoulos, Athanassios P. Kyritsis, Chrissa Sioka
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Diagnostics
Subjects:	theragnostics nuclear medicine thyroid cancer neuroendocrine tumors prostate cancer colorectal cancer
Online Access:	https://www.mdpi.com/2075-4418/13/19/3064

Similar Items

Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
by: Tasnim Khessib, MD, et al.
Published: (2023-11-01)

Molecularly imprinted polymers (MIPs): emerging biomaterials for cancer theragnostic applications
by: Min Seok Kang, et al.
Published: (2023-05-01)

Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs)
by: Michele Balma, et al.
Published: (2023-07-01)

Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates
by: Wolfgang Lilleby, et al.
Published: (2011-06-01)

Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics
by: Virginia Liberini, et al.
Published: (2022-06-01)

Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics
by: Olga V. Sergeeva, et al.
Published: (2025-01-01)

PSMA theragnostics for metastatic castration resistant prostate cancer
by: Hong Song, et al.
Published: (2022-08-01)

LncRNAs as Theragnostic Biomarkers for Predicting Radioresistance in Cancer: A Systematic Review and Meta-Analysis
by: Ping Lin, et al.
Published: (2022-05-01)

Polymeric Theragnostic Nanoplatforms for Bone Tissue Engineering
by: Kaushita Banerjee, et al.
Published: (2023-07-01)

Radiation Dosimetry of Theragnostic Pairs for Isotopes of Iodine in IAZA
by: Hans-S. Jans, et al.
Published: (2022-08-01)

Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics
by: Phuong-Thao Dang-Luong, et al.
Published: (2024-02-01)

Theragnostic Radionuclide Pairs for Prostate Cancer Management: <sup>64</sup>Cu/<sup>67</sup>Cu, Can Be a Budding Hot Duo
by: Anupriya Chhabra, et al.
Published: (2022-11-01)

Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives
by: Sankarprasad Bhuniya, et al.
Published: (2024-04-01)

PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
by: Martina Sollini, et al.
Published: (2019-10-01)

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
by: Aikaterini Kaloudi, et al.
Published: (2017-11-01)

Microfluidic Fabrication of Gadolinium-Doped Hydroxyapatite for Theragnostic Applications
by: Manuel Somoza, et al.
Published: (2023-01-01)

Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer
by: Fabio Volpe, et al.
Published: (2024-07-01)

Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis
by: Dessale M, et al.
Published: (2022-08-01)

Metabolic Priming as a Tool in Redox and Mitochondrial Theragnostics
by: Sónia A. Pinho, et al.
Published: (2023-05-01)

Goat milk extracellular vesicles: Separation comparison of natural carriers for theragnostic application
by: Jessie Santoro, et al.
Published: (2024-03-01)

Localized Therapeutic Approaches Based on Micro/Nanofibers for Cancer Treatment
by: Diana Alves, et al.
Published: (2023-03-01)

Research progress of cancer cell membrane coated nanoparticles for the diagnosis and therapy of breast cancer
by: Zixia Zhou, et al.
Published: (2023-09-01)

Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
by: Alex N. Frickenstein, et al.
Published: (2021-04-01)

Editorial: Metal nanoparticles in cancer: detection, diagnosis, therapy and their pharmacological assessment
by: Massimiliano Peana, et al.
Published: (2024-01-01)

Antitumor activity of 5-hydroxy-3′,4′,6,7-tetramethoxyflavone in glioblastoma cell lines and its antagonism with radiotherapy
by: Papapetrou Panagiota, et al.
Published: (2024-02-01)

Therapeutic effect of F127-folate@PLGA/CHL/IR780 nanoparticles on folate receptor-expressing cancer cells
by: Thi Ngoc Han Pham, et al.
Published: (2024-07-01)

Metallic nanoparticles for CT-guided imaging of tumors and their therapeutic applications
by: Deepak Gupta, et al.
Published: (2023-07-01)

Nanomagnet-facilitated pharmaco-compatibility for cancer diagnostics: Underlying risks and the emergence of ultrasmall nanomagnets
by: Divya S. Parimi, et al.
Published: (2022-06-01)

Theragnostic Glycol Chitosan-Conjugated Gold Nanoparticles for Photoacoustic Imaging of Regional Lymph Nodes and Delivering Tumor Antigen to Lymph Nodes
by: In-Cheol Sun, et al.
Published: (2021-06-01)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
by: Mai Lin, et al.
Published: (2022-10-01)

Nanobodies as Diagnostic and Therapeutic Tools for Cardiovascular Diseases (CVDs)
by: Lorena-Andreea Bocancia-Mateescu, et al.
Published: (2023-06-01)

Organotypic Hippocampal Slice Cultures from Adult Tauopathy Mice and Theragnostic Evaluation of Nanomaterial Phospho-TAU Antibody-Conjugates
by: Susanna Kemppainen, et al.
Published: (2023-05-01)

Synergistic Anti-Cancer Effects of Isocnicin and Radiotherapy in Glioblastoma: A Natural Compound’s Potential
by: Effrosyni Tsafa, et al.
Published: (2024-12-01)

Gender and disease-inclusive nomenclature consolidation of theragnostic target, prostate-specific membrane antigen (PSMA) to folate hydrolase-1 (FOLH1)
by: Marigdalia K. Ramirez-Fort, et al.
Published: (2024-02-01)

Vitamin D Deficiency as a Risk Factor for Myocardial Ischemia
by: Christina Batsi, et al.
Published: (2021-07-01)

Application of Metal Oxide Nanoparticles in Different Carcinomas
by: Nutan Rani, et al.
Published: (2024-12-01)

Editorial: Biointerfacing 2D nanomaterials and engineered heterostructures, volume II
by: Alfredo Maria Gravagnuolo, et al.
Published: (2024-12-01)

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
by: Cristina Müller, et al.
Published: (2019-07-01)

Myocardial perfusion imaging with <sup>99 m</sup>Tc - tetrofosmin SPECT in breast cancer patients that received postoperative radiotherapy: a case-control study
by: Sioka Chrissa, et al.
Published: (2011-11-01)

An NF-κB- and Therapy-Related Regulatory Network in Glioma: A Potential Mechanism of Action for Natural Antiglioma Agents
by: Evrysthenis Vartholomatos, et al.
Published: (2022-04-01)